Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders

Journal of Psychiatric Research

Volumn 34, Issue 2, 2000, Pages 89-98

  Serretti, Alessandro ^a   Lorenzi, Cristina ^a   Lilli, Roberta ^a   Smeraldi, Enrico ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Bipolar disorder; Follow up studies; Lithium; Serotonin receptors; Treatment outcome

Indexed keywords

LITHIUM; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; AFFECTIVE NEUROSIS; AGED; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LITHIUM CARBONATE; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 0034162075     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(00)00004-2     Document Type: Article

References (122)

1. Abou-Saleh MT. Who responds to prophylactic lithium therapy? British Journal of Psychiatry 1993;(Suppl. 21):202-6.
2. Anonymous. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. American Journal of Psychiatry. 151:1994;1-36.
3. Arranz M.J., Lin M.W., Powell J., Kerwin R., Collier D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 347:1996;1831-1832.
4. Arranz M.J., Erdmann J., Kirov G., Rietschel M., Sodhi M., Albus M., Ball D., Maier W., Davies N., Franzek E., Abusaad I., Weigelt B., Murray R., Shimron-Abarbanell D., Kerwin R., Propping P., Sham P., Nothen M.M., Collier D.A. 5-HT2A receptor and bipolar affective disorder: association studies in affected patients. Neuroscience Letters. 224:1997;95-98.
5. Arranz M.J., Munro J., Owen M.J., Spurlock G., Sham P.C., Zhao J., Kirov G., Collier D.A., Kerwin R.W. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Molecular Psychiatry. 3:1998;61-66.
6. Artigas F., Sarrias M.J., Martinez E., Gelpi E., Alvarez E., Udina C. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology. 99:1989;328-332.
7. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry. 51:1994;248-251.
8. Artigas F., Romero L., de Montigny C., Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends in Neurosciences. 19:1996;378-383.
9. Baptista T.J., Hernandez L., Burguera J.L., Burguera M., Hoebel B.G. Chronic lithium administration enhances serotonin release in the lateral hypothalamus but not in the hippocampus in rats. A microdialysis study. Journal of Neural Transmission-General Section. 82:1990;31-41.
10. Barbujani G., Sokal R.R. Genetic population structure of Italy. I. Geographic patterns of gene frequencies. Human Biology. 63:1991;253-272.
11. Belmaker R.H., Bersudsky Y., Agam G., Levine J., Kofman O. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory. Annual Review of Medicine. 47:1996;47-56.
12. Benkelfat C. Serotoninergic mechanisms in psychiatric disorders: new research tools, new ideas. International Clinical Psychopharmacology. 8:(Suppl.):1993;53-56.
13. Bradley C., Blakely R. Alternative splicing of the human serotonin transporter gene. Journal of Neurochemistry. 69:1997;1356-1367.
14. Brett P.M., Curtis D., Robertson M.M., Gurling H.M. Exclusion of the 5-HT1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior. American Journal of Psychiatry. 152:1995;437-440.
15. Burnet P.W., Mead A., Eastwood S.L., Lacey K., Harrison P.J., Sharp T. Repeated ECS differentially affects rat brain 5-HT1A and 5-HT2A receptor expression. Neuroreport. 6:1995;901-904.
16. Carli M., Reader T.A. Regulation of central serotonin transporters by chronic lithium: an autoradiographic study. Synapse. 27:1997;83-89.
17. Carli M., Afkhami-Dastjerdian S., Reader T.A. Effects of a chronic lithium treatment on cortical serotonin uptake sites and 5-HT1A receptors. Neurochemical Research. 22:1997;427-435.
18. Cassidy F., Murry E., Carroll B.J. Tryptophan depletion in recently manic patients treated with lithium. Biological Psychiatry. 43:1998;230-232.
19. Cavallini M.C., Di Bella D., Pasquale L., Henin M., Bellodi L. 5HT2C CYS23/SER23 polymorphism is not associated with obsessive-compulsive disorder. Psychiatry Research. 77:1998;97-104.
20. Cavazzoni P., Alda M., Turecki G., Rouleau G., Grof E., Martin R., Duffy A., Grof P. Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Research. 64:1996;91-96.
21. Chaouloff F., Gunn S.H., Young J.B. Serotonin does not mediate the adrenal catecholamine-releasing effect of acute lithium administration in rats. Psychoneuroendocrinology. 17:1992;135-144.
22. Chen C.H., Lee Y.R., Wei F.C., Koong F.J., Hwu H.G., Hsiao K.J. Lack of allelic association between 102 T/C polymorphism of serotonin receptor type 2A gene and schizophrenia in Chinese. Psychiatric Genetics. 7:1997;35-38.
23. Cohen J. Statistical power analysis for the behavioral sciences. 1988;Erlbaum, Hillsdale, NJ.
24. Cowen P.J. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clinical Neuropharmacology. 16:1993;S6-18.
25. Curtis D., Brynjolfsson J., Petursson H., Holmes D.S., Sherrington R., Brett P., Rifkin L., Murphy P., Moloney E., Holmes S., et al. Segregation and linkage analysis in five manic depression pedigrees excludes the 5HT1a receptor gene (HTR1A). Annals of Human Genetics. 57:1993;27-39.
26. De Montigny C., Chaput Y., Blier P. Classical and novel targets for antidepressant drugs: new pharmacological approaches to the therapy of depressive disorders. Int Acad Biomed Drug Res. 5:1993;8-17.
27. El-Mallakh S. Litihum: actions and mechanisms. Spiegel D. Progress in psychiatry. 1996;49-86 American Psychiatric Press, Washington, DC.
28. Endicott J., Spitzer R. A diagnostic interview: the schedule for affective disorders and schizophrenia. Archives of General Psychiatry. 35:1978;837-844.
29. Erdmann J., Shimron-Abarbanell D., Cichon S., Albus M., Maier W., Lichtermann D., Minges J., Reuner U., Franzek E., Ertl M.A., et al. Systematic screening for mutations in the promoter and the coding region of the 5-HT1A gene. American Journal of Medical Genetics. 60:1995;393-399.
30. Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W., Korner J., Bondy B., Chen K., Shih J.C., Knapp M., Propping P., Nothen M.M. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum. Genet. 97:1996;614-619.
31. Fargin A., Raymond J.R., Lohse M.J., Kobilka B.K., Caron M.G., Lefkowitz R.J. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature. 335:1988;358-360.
32. Franchini L., Gasperini M., Smeraldi E. A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. Journal of Affective Disorders. 32:1994;225-231.
33. Franchini L., Zanardi R., Gasperini M., Perez J., Smeraldi E. Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. Journal of Affective Disorders. 38:1996;67-69.
34. Franchini L, Scherillo P, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. European Archives of Psychiatry & Clinical Neuroscience 2000; (in press).
35. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry. 48:1991;851-855.
36. Gasparini P., Estivill X., Volpini V., Totaro A., Castellvi-Bel S., Govea N., Mila M., Della Monica M., Ventruto V., De Benedetto M., Stanziale P., Zelante L., Mansfield E.S., Sandkuijl L., Surrey S., Fortina P. Linkage of DFNB1 to non-syndromic neurosensory autosomal-recessive deafness in Mediterranean families. European Journal of Human Genetics. 5:1997;83-88.
37. Gasperini M., Scherillo P., Manfredonia M., Franchini L., Smeraldi E. A study of relapses in subjects with mood disorder on lithium treatment. European Neuropsychopharmacology. 3:1993;103-110.
38. Gasperini M., Scherillo P., Manfredonia M.G., Franchini L., Smeraldi E. A study of relapses in subjects with mood disorder on lithium treatment. European Neuropsychopharmacology. 3:1993;103-110.
39. Gatti F., Bellini L., Gasperini M., Perez J., Zanardi R., Smeraldi E. Fluvoxamine alone in the treatment of delusional depression. American Journal of Psychiatry. 153:1996;414-416.
40. Gelenberg A.J., Carroll J.A., Baudhuin M.G., Jefferson J.W., Greist J.H. The meaning of serum lithium levels in maintenance therapy of mood disorders: a review of the literature. Journal of Clinical Psychiatry. 50:1989;17-22.
41. Gilliam T.C., Freimer N.B., Kaufmann C.A., Powchik P.P., Bassett A.S., Bengtsson U., Wasmuth J.J. Deletion mapping of DNA markers to a region of chromosome 5 that cosegregates with schizophrenia. Genomics. 5:1989;940-944.
42. Goldberg J.F., Harrow M., Leon A.C. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacology Bulletin. 32:1996;47-54.
43. Goldman D. Candidate genes in alcoholism. Clinical Neuroscience. 3:1995;174-181.
44. Goodwin F., Jamison K. Manic-depressive illness. 1990;Oxford University Press, New York.
45. Goodwin G.M. The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 13:1989;445-451.
46. Grof P., Alda M., Grof E., Zvolsky P., Walsh M. Lithium response and genetics of affective disorders. Journal of Affective Disorders. 32:1994;85-95.
47. Gutierrez B., Fananas L., Arranz M.J., Valles V., Guillamat R., van Os J., Collier D. Allelic association analysis of the 5-HT2C receptor gene in bipolar affective disorder. Neuroscience Letters. 212:1996;65-67.
48. Gutierrez B., Bertranpetit J., Collier D., Arranz M.J., Valles V., Guillamat R., Van Os J., Fananas L. Genetic variation of the 5-HT2A receptor gene and bipolar affective disorder. Human Genetics. 100:1997;582-584.
49. Hallmayer J., Maier W., Schwab S., Ertl M.A., Minges J., Ackenheil M., Lichtermann D., Wildenauer D.B. No evidence of linkage between the dopamine D2 receptor gene and schizophrenia. Psychiatry Research. 52:1994;203-215.
50. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social & Clinical Psychology. 6:1967;278-296.
51. Hawi Z., Myakishev M.V., Straub R.E., O'Neill A., Kendler K.S., Walsh D., Gill M. No association or linkage between the 5-HT2a/T102C polymorphism and schizophrenia in Irish families. American Journal of Medical Genetics. 74:1997;370-373.
52. Heath M.J., Hen R. Serotonin receptors. Genetic insights into serotonin function. Current Biology. 5:1995;997-999.
53. Holmes C., Arranz M.J., Powell J.F., Collier D.A., Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Human Molecular Genetics. 7:1998;1507-1509.
54. Hotta I., Yamawaki S., Segawa T. Long-term lithium treatment causes serotonin receptor down-regulation via serotonergic presynapses in rat brain. Neuropsychobiology. 16:1986;19-26.
55. Inayama Y., Yoneda H., Sakai T., Ishida T., Nonomura Y., Kono Y., Takahata R., Koh J., Sakai J., Takai A., Inada Y., Asaba H. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. American Journal of Medical Genetics. 67:1996;103-105.
56. Ishigaki T., Xie D.W., Liu J.C., Nakamura Y., Zhang H.Y., Tani K., Shimazu Y., Chen K., Shih J.C., Miyasato K., Ohara K. Intact 5-HT2A receptor exons and the adjoining intron regions in schizophrenia. Neuropsychopharmacology. 14:1996;339-347.
57. Jacobs B.L., Fornal C.A. Serotonin and behavior. A general hypothesis. Bloom F.E., Kupfer D.J. Psychopharmacology: The fourth generation of progress. 1995;461-469 Raven Press, New York.
58. Jonsson E., Nothen M.M., Bunzel R., Propping P., Sedvall G. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 347:1996;1831.
59. Joober R., Benkelfat C., Brisebois K., Toulouse A., Turecki G., Lal S., Bloom D., Labelle A., Lalonde P., Fortin D., Alda M., Palmour R., Rouleau G.A. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. Journal of Psychiatry & Neuroscience. 24:1999;141-146.
60. Kawanishi C., Hanihara T., Shimoda Y., Suzuki K., Sugiyama N., Onishi H., Miyakawa T., Yamada Y., Kosaka K. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HT1A and 5-HT2A receptor genes. American Journal of Psychiatry. 155:1998;1275-1277.
61. Kawanishi Y., Harada S., Tachikawa H., Okubo T., Shiraishi H. Novel Mutations in the Promoter and Coding Region of the Human 5-Ht1a Receptor Gene and Association Analysis in Schizophrenia. American Journal of Medical Genetics. 81:1998;434-439.
62. Keller M.B., Lavori P.W., Friedman B., Nielsen E., Endicott J., McDonald-Scott P., Andreasen N.C. The Longitudinal Interval Follow-up Evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry. 44:1987;540-548.
63. Kobilka B.K., Frielle T., Collins S., Yang-Feng T., Kobilka T.S., Francke U., Lefkowitz R.J., Caron M.G. An intronless gene encoding a potential member of the family of receptors coupled to guanine nucleotide regulatory proteins. Nature. 329:1987;75-79.
64. Kouzmenko A.P., Scaffidi A., Pereira A.M., Hayes W.L., Copolov D.L., Dean B. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Human Heredity. 49:1999;103-105.
65. Lacaille J.C., Cloutier S., Reader T.A. Lithium reduced synaptic transmission and increased neuronal excitability without altering endogenous serotonin, norepinephrine and dopamine in rat hippocampal slices in vitro. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 16:1992;397-412.
66. Lahiri D.K., Nurnberger J.I.J. A rapid non-enzimatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acid Research. 19:1991;5444.
67. Lam S., Shen Y., Nguyen T., Messier T.L., Brann M., Comings D., George S.R., Bf O.D. A serotonin receptor gene (5HT1A) variant found in a Tourette's syndrome patient. Biochemical & Biophysical Research Communications. 219:1996;853-858.
68. Lappalainen J., Zhang L., Dean M., Oz M., Ozaki N., Yu D.H., Virkkunen M., Weight F., Linnoila M., Goldman D. Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics. 27:1995;274-279.
69. Leckman J.F., Sholomskas D., Thompson W.D., Belanger A., Weissman M.M. Best estimate of lifetime psychiatric diagnosis: a methodological study. Archives of General Psychiatry. 39:1982;879-883.
70. Lentes K.U., Hinney A., Ziegler A., Rosenkranz K., Wurmser H., Barth N., Jacob K., Coners H., Mayer H., Grzeschik K.H., Schafer H., Remschmidt H., Pirke K.M., Hebebrand J. Evaluation of a Cys23Ser mutation within the human 5-HT2C receptor gene: no evidence for an association of the mutant allele with obesity or underweight in children, adolescents and young adults. Life Sciences. 61:1997;PL9-16.
71. Lin C.H., Tsai S.J., Yu Y.W.Y., Song H.L., Tu P.C., Sim C.B., Hsu C.P., Yang K.H., Hong C.J. No evidence for association of serotonin-2A receptor variant (102 T/C) with schizophrenia or clozapine response in a Chinese population. Neuroreport. 10:1999;57-60.
72. Lipp O, Mahieu B, Souery D, Serretti A, Cavallini C, Verga M, Van Broeckhoven C, Macciardi F, Mendlewicz J. Molecular genetics of bipolar disorders: implication for psychotropic drugs. Xth Congress of the European College of Neuropsychopharmacology, Vienna, Austria, 1997.
73. Mahieu B., Souery D., Lipp O., Mendelbaum K., Verheyen G., De Maertelaer V., Van Broeckhoven C., Mendlewicz J. No association between bipolar affective disorder and a serotonin receptor (5-HT2A) polymorphism. Psychiatry Research. 70:1997;65-69.
74. Maj M., Del Vecchio M., Starace F., Pirozzi R., Kemali D. Prediction of affective psychoses response to lithium prophylaxis. The role of socio-demographic, clinical, psychological and biological variables. Acta Psychiatrica Scandinavica. 69:1984;37-44.
75. Maj M., Arena F., Lovero N., Pirozzi R., Kemali D. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder. Pharmacopsychiatry. 18:1985;309-313.
76. Maj M., Pirozzi R., Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. Journal of Affective Disorders. 17:1989;237-241.
77. Maj M., Pirozzi R., Magliano L., Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. American Journal of Psychiatry. 155:1998;30-35.
78. Malhotra A.K., Goldman D., Buchanan R., Breier A., Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 347:1996;1830-1831.
79. Manji H.K., Hsiao J.K., Risby E.D., Oliver J., Rudorfer M.V., Potter W.Z. The mechanisms of action of lithium. I. Effects on serotoninergic and noradrenergic systems in normal subjects. Archives of General Psychiatry. 48:1991;505-512.
80. Martin J.R., Bos M., Jenck F., Moreau J., Mutel V., Sleight A.J., Wichmann J., Andrews J.S., Berendsen H.H., Broekkamp C.L., Ruigt G.S., Kohler C., Delft A.M. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. Journal of Pharmacology & Experimental Therapeutics. 286:1998;913-924.
81. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry. 48:1991;764-770.
82. Mendlewicz J., Fieve R.R., Stallone F., Fleiss J.L. Genetic history as a predictor of lithium response in manic-depressive illness. Lancet. 1:1972;599-600.
83. Morabito A., Gasperini M., Macciardi F., Smeraldi E. Possible relationship between outcome in primary affective disorders treated with lithium and family history. Advances in Biochemical Psychopharmacology. 32:1982;157-163.
84. Moreau J.L., Bos M., Jenck F., Martin J.R., Mortas P., Wichmann J. 5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. European Neuropsychopharmacology. 6:1996;169-175.
85. Nakamura T., Matsushita S., Nishiguchi N., Kimura M., Yoshino A., Higuchi S. Association of a polymorphism of the 5HT2A receptor gene promoter region with alcohol dependence. Molecular Psychiatry. 4:1999;85-88.
86. Nakhai B., Nielsen D.A., Linnoila M., Goldman D. Two naturally occurring amino acid substitutions in the human 5-HT1A receptor: glycine 22 to serine 22 and isoleucine 28 to valine 28. Biochemical & Biophysical Research Communications. 210:1995;530-536.
87. O'Connell R.A., Mayo J.A., Flatow L., Cuthbertson B., O'Brien B.E. British Journal of Psychiatry. 159:1991;123-129.
88. Odagaki Y., Koyama T., Matsubara S., Matsubara R., Yamashita I. Effects of chronic lithium treatment on serotonin binding sites in rat brain. Journal of Psychiatric Research. 24:1990;271-277.
89. Ohara K., Nagai M., Tani K., Tsukamoto T. Schizophrenia and the serotonin-2A receptor promoter polymorphism. Psychiatry Research. 85:1999;221-224.
90. Oliveira J.R.M., Zatz M. The study of genetic polymorphisms related to serotonin in Alzheimer's disease: new perspective in a heterogenic disorder. Brazilian Journal of Medical & Biological Research. 32:1999;463-467.
91. Oruc L., Verheyen G.R., Furac I., Jakovljevic M., Ivezic S., Raeymaekers P., Van Broeckhoven C. Association analysis of the 5-HT2C receptor and 5-HT transporter genes in bipolar disorder. American Journal of Medical Genetics. 74:1997;504-506.
92. Ozaki N. [Molecular genetic approach to schizophrenia: direct analysis of 5-HT receptor genes]. Nihon Shinkei Seishin Yakurigaku Zasshi. 16:1996;175-180.
93. Page C., Benaim S., Lappin F. A long-term retrospective follow-up study of patients treated with prophylactic lithium carbonate. British Journal of Psychiatry. 150:1987;175-179.
94. Pandey S.C., Lumeng L., Li T.K. Serotonin2C receptors and serotonin2C receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring and alcohol-nonpreferring rats. Alcoholism, Clinical & Experimental Research. 20:1996;1038-1042.
95. Pei Q., Leslie R.A., Grahame-Smith D.G., Zetterstrom T.S. 5-HT efflux from rat hippocampus in vivo produced by 4-aminopyridine is increased by chronic lithium administration. Neuroreport. 6:1995;716-720.
96. Price L.H., Charney D.S., Delgado P.L., Heninger G.R. Lithium treatment and serotoninergic function. Archives of General Psychiatry. 46:1989;13-19.
97. Price L.H., Charney D.S., Delgado P.L., Heninger G.R. Lithium and serotonin function: implications for the serotonin hypothesis of depression. Psychopharmacology. 100:1990;3-12.
98. Sasaki T., Hattori M., Fukuda R., Kunugi H., Nanko S. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet. 347:1996;1832.
99. Schou M. Lithium treatment of manic depressive illness. A practical guide. 1989;Karger, Basel.
100. Segman R.H., Ebstein R.P., Heresco-Levy U., Gorfine M., Avnon M., Gur E., Nemanov L., Lerer B. Schizophrenia, chronic hospitalization and the 5-HT2C receptor gene. Psychiatric Genetics. 7:1997;75-78.
101. Serretti A., Lilli R., Lorenzi C., Gasperini M., Smeraldi E. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. International Journal of Neuropsychopharmacology. 1:1998;125-129.
102. Serretti A., Lilli R., Lorenzi C., Franchini L., DiBella D., Catalano M., Smeraldi E. Dopamine receptor D2, D4, GABAA Alpha-1 subunit genes and response to lithium prophylaxis in mood disorders. Psychiatry Research. 87:1999;7-19.
103. Serretti A., Lilli R., Lorenzi C., Gasperini M., Smeraldi E. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. Journal of Psychiatric Research. 33:1999;371-377.
104. Sharp T., Bramwell S.R., Lambert P., Grahame-Smith D.G. Effect of short- and long-term administration of lithium on the release of endogenous 5-HT in the hippocampus of the rat in vivo and in vitro. Neuropharmacology. 30:1991;977-984.
105. Shinkai T., Ohmori O., Kojima H., Terao T., Suzuki T., Abe K. Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan. Human Heredity. 48:1998;212-215.
106. Smeraldi E., Petroccione A., Gasperini M., Macciardi F., Orsini A. The search for genetic homogeneity in affective disorders. Journal of Affective Disorders. 7:1984;99-107.
107. Smeraldi E., Petroccione A., Gasperini M., Macciardi F., Orsini A., Kidd K.K. Outcomes on lithium treatment as a tool for genetic studies in affective disorders. Journal of Affective Disorders. 6:1984;139-151.
108. Souery D., Lipp O., Serretti A., Mahieu B., Rivelli S.K., Cavallini C., Ackenheil M., Adolfsson R., Aschauer H., Blackwood D., Dam H., Delcoigne B., Demartelaer V., Dikeos D., Fuchshuber S., Heiden M., Jablensky A., Jakovljevic M., Kessing L., Lerer B., Macedo A., Mellerup T., Milanova V., Muir W., Nylander P.O., Onchev G., Oruc L., Papadimitriou G.N., Pekkarinen P., Peltonen L., Pinto de Azevedo M.H., Pull C., Shapira B., Smeraldi E., Staner L., Stefanis C., Verga M., Raeymaekers P., Macciardi F., Van Broeckhoven C., Mendlewicz J. European Collaborative Project on Affective Disorders: Interactions between genetic and psychosocial vulnerability factors. Psychiatric Genetics. 8:1998;197-205.
109. Spurlock G., Heils A., Holmans P., Williams J., D'Souza U.M., Cardno A., Murphy K.C., Jones L., Buckland P.R., McGuffin P., Lesch K.P., Owen M.J. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Molecular Psychiatry. 3:1998;42-49.
110. Tay A.H., Lim L.C., Lee W.L., Wong K.E., Wong L.Y., Tsoi W.F. Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore. Human Heredity. 47:1997;298-300.
111. Terwilliger J., Ott J. Handbook for Human Genetic Linkage. 1994;Johns Hopkins University Press.
112. Treiser S.L., Cascio C.S., Tl O.D., Thoa N.B., Jacobowitz D.M., Kellar K.J. Lithium increases serotonin release and decreases serotonin receptors in the hippocampus. Science. 213:1981;1529-1531.
113. Turecki G., Alda M., Grof P., Martin R., Cavazzoni P.A., Duffy A., Maciel P., Rouleau G.A. No association between chromosome-18 markers and lithium-responsive affective disorders. Psychiatry Research. 63:1996;17-23.
114. Verga M., Macciardi F., Cohen S., Pedrini S., Smeraldi E. No association between schizophrenia and the serotonin receptor 5HTR2a in an Italian population. American Journal of Medical Genetics. 74:1997;21-25.
115. Williams J., Spurlock G., McGuffin P., Mallet J., Nothen M.M., Gill M., Aschauer H., Nylander P.O., Macciardi F., Owen M.J. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet. 347:1996;1294-1296.
116. Xie D.W., Deng Z.L., Ishigaki T., Nakamura Y., Suzuki Y., Miyasato K., Ohara K., Ohara K. The gene encoding the 5-HT1A receptor is intact in mood disorders. Neuropsychopharmacology. 12:1995;263-268.
117. Xie E., Zhu L., Zhao L., Chang L.S. The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and alternatively spliced variant. Genomics. 35:1996;551-561.
118. Young R., Biggs J., Ziegler V., Meyer D. A rating scale for mania: reliability, validity and sensitivity. British Journal of Psychiatry. 133:1978;429-435.
119. Zanardi R., Franchini L., Gasperini M., Perez J., Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. American Journal of Psychiatry. 153:1996;1631-1633.
120. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should Pindolol be associated with Paroxetine to improve the antidepressant response? Journal of Clinical Psychopharmacology. 17:1997;446-450.
121. Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a double-blind controlled study. Journal of Clinical Psychiatry 2000; (in press).
122. Zhang H.Y., Ishigaki T., Tani K., Chen K., Shih J.C., Miyasato K., Ohara K., Ohara K. Serotonin 2A receptor gene polymorphism in mood disorders. Biological Psychiatry. 41:1997;768-773.